Publications by authors named "Emily Tarco"

Claim this Profile
G
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.
Argun Akcakanat, Xiaofeng Zheng, Christian X Cruz Pico, Tae-Beom Kim, Ken Chen, Emily Tarco

Clin Cancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Yan Xing, Nancy U Lin, Matthew A Maurer, Huiqin Chen, Armeen Mahvash, Emily Tarco

Breast Cancer Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor.
Santanu Adhikary, Deepavali Chakravarti, Christopher Terranova, Isha Sengupta, Mayinuer Maitituoheti, Emily Tarco

Nat Commun· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Kurt W Evans, Erkan Yuca, Argun Akcakanat, Stephen M Scott, Natalia Paez Arango, Emily Tarco

Clin Cancer Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.
Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, Ken Chen, Xiaofeng Zheng, Emily Tarco

PLoS One· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.
Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, Ken Chen, Xiaofeng Zheng, Emily Tarco

PLoS One· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.
Arvind Dasari, Alexandria Phan, Sanjay Gupta, Asif Rashid, Sai-Ching Jim Yeung, Emily Tarco

Endocr Relat Cancer· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
Ana M Gonzalez-Angulo, Ian Krop, Argun Akcakanat, Huiqin Chen, Shuying Liu, Emily Tarco

J Natl Cancer Inst· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of biospecimen variables on proteomic biomarkers in breast cancer.
Funda Meric-Bernstam, Argun Akcakanat, Huiqin Chen, Aysegul Sahin, Emily Tarco

Clin Cancer Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.
Takafumi Sangai, Argun Akcakanat, Huiqin Chen, Emily Tarco, Yun Wu

Clin Cancer Res· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.
Mitchell J Frederick, Amy J VanMeter, Mayur A Gadhikar, Ying C Henderson, Hui Yao, Emily Tarco

Am J Pathol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
Yun Gong, William Sweet, Yi-Jing Duh, Larry Greenfield, Emily Tarco

Am J Clin Pathol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
Lavinia P Middleton, Kathy M Price, Pamela Puig, Lori J Heydon, Emily Tarco

Arch Pathol Lab Med· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.
Yun Gong, William Sweet, Yi-Jing Duh, Larry Greenfield, Yuan Fang, Emily Tarco

Am J Clin Pathol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer.
Toru Kawamoto, Savitri Krishnamurthy, Emily Tarco, Smita Trivedi, Ignacio I Wistuba

Gastrointest Cancer Res· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A human papillomavirus testing system in women with abnormal Pap results: a comparison study with follow-up biopsies.
Ming Guo, Shobha J Patel, Marilyn Chovanec, Yee Jee Jan, Emily Tarco

Acta Cytol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma.
Hyung Ju C Shin, Dong M Shin, Emily Tarco, Nour Sneige

Cancer· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis